INSMED INC Payments to Acquire Marketable Securities
INSMED INC (INSM) reported Payments to Acquire Marketable Securities of $399.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- INSMED INC payments to acquire marketable securities for the quarter ending 2026-06-30 was $399.23M, a 44.29% increase year-over-year.
- INSMED INC payments to acquire marketable securities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- INSMED INC payments to acquire marketable securities for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- INSMED INC payments to acquire marketable securities for the quarter ending 2025-09-30 was $1.18B, a 18.51% increase year-over-year.
- INSMED INC payments to acquire marketable securities for fiscal 2025 was $2.09B, a 32.64% increase from fiscal 2024.
- INSMED INC payments to acquire marketable securities for fiscal 2024 was $1.58B, a 167.91% increase from fiscal 2023.
- INSMED INC payments to acquire marketable securities for fiscal 2023 was $588.73M, a 490.47% increase from fiscal 2022.
- INSMED INC payments to acquire marketable securities for fiscal 2022 was $99.71M, a 98.25% increase from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 3 month as first filed | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $399.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $399.23M 10-Q · filed 2026-08-06 | $399.23M derived: sum of 3 quarters · filed 2026-08-06 | $1.58B derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $1.18B derived: sum of 3 quarters · filed 2026-05-07 | $1.46B derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.18B derived: sum of 2 quarters · filed 2026-02-19 | $1.46B derived: sum of 3 quarters · filed 2026-08-06 | $2.09B 10-K · filed 2026-02-19 | |
| 2025-09-30 | $1.18B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $1.46B derived: sum of 2 quarters · filed 2026-08-06 | $2.09B 10-Q · filed 2025-10-30 | $2.67B derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $276.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $907.20M 10-Q · filed 2026-08-06 | $1.48B derived: sum of 3 quarters · filed 2026-08-06 | $2.48B derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $630.52M 10-Q · filed 2026-05-07 | $1.21B derived: sum of 2 quarters · filed 2026-05-07 | $2.21B derived: sum of 3 quarters · filed 2026-05-07 | $2.21B derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $577.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $1.58B derived: sum of 2 quarters · filed 2026-02-19 | $1.58B derived: sum of 3 quarters · filed 2026-02-19 | $1.58B 10-K · filed 2026-02-19 | |
| 2024-09-30 | $999.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $999.78M derived: sum of 2 quarters · filed 2025-10-30 | $999.78M 10-Q · filed 2025-10-30 | $1.30B derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $296.04M derived: sum of 3 quarters · filed 2026-02-19 | $296.04M derived: sum of 4 quarters · filed 2026-02-19 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $300.00M 10-Q · filed 2024-05-09 | $296.04M derived: sum of 2 quarters · filed 2026-02-19 | $296.04M derived: sum of 3 quarters · filed 2026-02-19 | $588.73M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $296.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $296.04M derived: sum of 2 quarters · filed 2026-02-19 | $588.73M derived: sum of 3 quarters · filed 2026-02-19 | $588.73M 10-K · filed 2026-02-19 | |
| 2023-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $292.69M derived: sum of 2 quarters · filed 2024-10-31 | $292.69M 10-Q · filed 2024-10-31 | $292.69M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-06-30 | $292.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $292.69M 10-Q · filed 2024-08-08 | $292.69M derived: sum of 3 quarters · filed 2025-02-20 | $292.69M derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $0.00 derived: sum of 4 quarters · filed 2025-02-20 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $99.71M 10-K · filed 2025-02-20 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-26 | $0.00 derived: sum of 2 quarters · filed 2023-10-26 | $99.71M 10-Q · filed 2023-10-26 | $150.00M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $99.71M 10-Q · filed 2023-08-03 | $150.00M derived: sum of 3 quarters · filed 2024-02-22 | $150.00M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | $99.71M 10-Q · filed 2023-05-04 | $150.00M derived: sum of 2 quarters · filed 2024-02-22 | $150.00M derived: sum of 3 quarters · filed 2024-02-22 | $150.00M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | $50.29M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $50.29M derived: sum of 2 quarters · filed 2024-02-22 | $50.29M derived: sum of 3 quarters · filed 2024-02-22 | $50.29M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $0.00 derived: sum of 2 quarters · filed 2022-10-27 | $0.00 10-Q · filed 2022-10-27 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |